Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519027 | 0.89 | LMNA (0.58) | ALDH1A1KDM4ELMNA | |
| SCHEMBL19691124 | 0.85 | NR4A2 (0.47) | MAPTNR4A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL3050804 | 0.85 | NR4A2 (0.47) | MAPTNR4A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL1849453 | 0.85 | NR4A2 (0.69) | MAPTNR4A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL22955211 | 0.82 | PLK1 (0.47) | MAPTNR4A2ALDH1A1KMT2AMEN1 | |
| SCHEMBL22955034 | 0.82 | PLK1 (0.44) | MAPTNR4A2ALDH1A1KMT2AMEN1 | |
| SCHEMBL18938520 | 0.80 | KMT2A (0.44) | MAPTNR4A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL784862 | 0.79 | LMNA (0.44) | MAPTALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL29965768 | 0.77 | POLB (0.72) | MAPTNR4A2ALDH1A1KMT2AKDM4E | |
| SCHEMBL535878 | 0.77 | POLB (0.72) | MAPTNR4A2ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | MAPT 3454/4885NR4A2 665/4885ALDH1A1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.